Category: Therapeutics
-
RougeTx Launches with HHT as Lead Therapeutic Program
RougeTx, a new biotechnology company focused on vascular disease, has launched with $58 million in Series A financing to advance RTX-001, an investigational treatment…
-
Tectonic Reports Early Safety Data for TX2100: What It Means for HHT Research
The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow. On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy…
-
Advancing Clinical Research in HHT: Introducing the Harmony-HHT Clinical Trial.
Tuesday, October 27, 2026 · 12:00 PM ET | Register now!
-
FDA Adds Boxed Warning to Ferric Carboxymaltose Following Petition Led by Cure HHT’s Dr. Scott Olitsky
When something in HHT care isn’t working the way it should, speaking up matters. On August 13, 2026, the US Food and Drug Administration…
-
A History of Pazopanib
There are no FDA-approved therapeutics for the treatment of HHT. Cure HHT sought to change that. In many ways, the history of pazopanib is…
-
A major milestone for HHT treatment!
I am reaching out to share the news of a truly momentous milestone for both our organization and our community; the Pazopanib clinical trial…
-
Pazopanib Clinical Trial: Q&A
The Pazopanib clinical trial has launched, and the road to reach this breakthrough milestone has been more involved and hard-fought than many may realize.…